Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial

[October 01, 2014]  (Reuters) - Ardelyx Inc said its experimental drug to treat constipation-related irritable bowel syndrome achieved the main goal of increasing bowel movement compared to a placebo in a mid-stage study involving 371 patients.

Ardelyx licensed the drug, tenapanor, to AstraZeneca Plc in October 2012.

The companies are also testing the drug for two kidney-related indications.

(Reporting by Amrutha Penumudi in Bangalore; Editing by Ted Kerr)

[© 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.